The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis
- PMID: 26847182
- DOI: 10.1007/s00345-016-1772-z
The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis
Abstract
Purpose: The purpose of this study was to assess the diagnostic accuracy of 18F-fluorodeoxyglucose with positron emission tomography and computed tomography (FDG-PET-CT) to predict nodal metastases in patients with bladder cancer (BC) scheduled to undergo radical cystectomy (RC).
Methods: We retrospectively reviewed records of patients diagnosed with BC and scheduled to undergo RC at our center from January 2011 through February 2015, who also underwent FDG-PET-CT at the time of diagnosis. All patients underwent RC and an extended pelvic lymph node dissection as the reference standard. The primary endpoints were the sensitivity, specificity and overall accuracy of FDG-PET-CT in detecting lymph node metastasis. We also examined its accuracy in identifying distant metastasis. In addition, we conducted a protocol-driven systematic review and meta-analysis of accuracy of FDG-PET-CT for preoperative staging of BC, as compared to CT alone, as reported in individual studies. To assess the methodological quality of eligible studies, we used the QUADAS-2 tool (a revised tool for the Quality Assessment of Diagnostic Accuracy Studies) and pooled diagnostic accuracy measures using Meta-DiSc statistical software.
Results: For detecting nodal metastases in 78 patients, the sensitivity of FDG-PET-CT was 0.56 (95 % CI 0.29-0.80) and the specificity, 0.98 (95 % CI 0.91-1.00). Pooled sensitivity and specificity for detecting lymph node metastasis were 0.57 and 0.95, respectively. Positive likelihood ratio was 9.02. All lesions that were suspicious for distant metastasis were found to be positive on biopsy.
Conclusion: FDG-PET-CT was more accurate than CT alone in staging BC in patients undergoing surgery. Standardization of FDG-PET-CT protocol and cost-effectiveness analysis are required before widespread implementation of this technology.
Keywords: Bladder cancer; Lymph nodes; Positron emission tomography; Preoperative staging; Urinary bladder neoplasms.
Similar articles
-
Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.Cochrane Database Syst Rev. 2021 Nov 9;11(11):CD012325. doi: 10.1002/14651858.CD012325.pub2. Cochrane Database Syst Rev. 2021. PMID: 34753195 Free PMC article.
-
The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.Health Technol Assess. 2011 Sep;15(35):1-192, iii-iv. doi: 10.3310/hta15350. Health Technol Assess. 2011. PMID: 21958472 Free PMC article.
-
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.Eur Urol Oncol. 2022 Feb;5(1):1-17. doi: 10.1016/j.euo.2021.08.001. Epub 2021 Sep 17. Eur Urol Oncol. 2022. PMID: 34538770
-
Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation.Health Technol Assess. 2011 Jan;15(4):iii-iv, 1-134. doi: 10.3310/hta15040. Health Technol Assess. 2011. PMID: 21276372 Free PMC article.
-
A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.Health Technol Assess. 2010 Oct;14(50):1-103. doi: 10.3310/hta14500. Health Technol Assess. 2010. PMID: 21044553
Cited by
-
Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+).Cancers (Basel). 2022 Oct 27;14(21):5286. doi: 10.3390/cancers14215286. Cancers (Basel). 2022. PMID: 36358705 Free PMC article. Review.
-
Small cell carcinoma of the bladder: Review of pathogenesis, presentation, and management.Bladder Cancer. 2025 Aug 18;11(3):23523735251370956. doi: 10.1177/23523735251370956. eCollection 2025 Jul-Sep. Bladder Cancer. 2025. PMID: 40842970 Free PMC article. Review.
-
Lymph Node Dissection in Upper Tract Urothelial Carcinoma: Current Status and Future Perspectives.Curr Oncol Rep. 2023 Nov;25(11):1327-1344. doi: 10.1007/s11912-023-01460-y. Epub 2023 Oct 6. Curr Oncol Rep. 2023. PMID: 37801187 Free PMC article. Review.
-
Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence.Cancers (Basel). 2023 May 28;15(11):2951. doi: 10.3390/cancers15112951. Cancers (Basel). 2023. PMID: 37296913 Free PMC article. Review.
-
Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review.Arab J Urol. 2020 Dec 10;19(1):59-66. doi: 10.1080/2090598X.2020.1858012. Arab J Urol. 2020. PMID: 33763249 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical